Bebawy M - Search Results

1

Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies.

Marin L, Traini D, Bebawy M, Colombo P, Buttini F, Haghi M, Ong HX, Young P. Marin L, et al. Among authors: bebawy m. Eur J Pharm Biopharm. 2013 Aug;84(3):566-72. doi: 10.1016/j.ejpb.2013.01.021. Epub 2013 Mar 7. Eur J Pharm Biopharm. 2013. PMID: 23474382

2

Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro.

Haghi M, Bebawy M, Colombo P, Forbes B, Lewis DA, Salama R, Traini D, Young PM. Haghi M, et al. Among authors: bebawy m. Eur J Pharm Biopharm. 2014 Jan;86(1):38-45. doi: 10.1016/j.ejpb.2013.02.020. Epub 2013 Mar 22. Eur J Pharm Biopharm. 2014. PMID: 23528797

3

Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management.

Marin L, Colombo P, Bebawy M, Young PM, Traini D. Marin L, et al. Among authors: bebawy m. Expert Opin Drug Deliv. 2011 Sep;8(9):1205-20. doi: 10.1517/17425247.2011.588697. Epub 2011 May 26. Expert Opin Drug Deliv. 2011. PMID: 21615218 Review.

4

In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.

Ong HX, Benaouda F, Traini D, Cipolla D, Gonda I, Bebawy M, Forbes B, Young PM. Ong HX, et al. Among authors: bebawy m. Eur J Pharm Biopharm. 2014 Jan;86(1):83-9. doi: 10.1016/j.ejpb.2013.06.024. Epub 2013 Jul 10. Eur J Pharm Biopharm. 2014. PMID: 23851077

5

Epithelial profiling of antibiotic controlled release respiratory formulations.

Ong HX, Traini D, Bebawy M, Young PM. Ong HX, et al. Among authors: bebawy m. Pharm Res. 2011 Sep;28(9):2327-38. doi: 10.1007/s11095-011-0462-1. Epub 2011 May 26. Pharm Res. 2011. PMID: 21614637

6

Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia.

Haghi M, Traini D, Bebawy M, Young PM. Haghi M, et al. Among authors: bebawy m. Mol Pharm. 2012 Jun 4;9(6):1717-26. doi: 10.1021/mp200620m. Epub 2012 May 23. Mol Pharm. 2012. PMID: 22574661

7

Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.

Ong HX, Traini D, Bebawy M, Young PM. Ong HX, et al. Among authors: bebawy m. Antimicrob Agents Chemother. 2013 Jun;57(6):2535-40. doi: 10.1128/AAC.00306-13. Epub 2013 Mar 18. Antimicrob Agents Chemother. 2013. PMID: 23507281 Free PMC article.

8

Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model.

Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Haghi M, et al. Among authors: bebawy m. Drug Dev Ind Pharm. 2010 Oct;36(10):1207-14. doi: 10.3109/03639041003695113. Drug Dev Ind Pharm. 2010. PMID: 20374185

9

Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.

Ong HX, Traini D, Cipolla D, Gonda I, Bebawy M, Agus H, Young PM. Ong HX, et al. Among authors: bebawy m. Pharm Res. 2012 Dec;29(12):3335-46. doi: 10.1007/s11095-012-0827-0. Epub 2012 Jul 26. Pharm Res. 2012. PMID: 22833052

10

Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs.

Mamlouk M, Young PM, Bebawy M, Haghi M, Mamlouk S, Mulay V, Traini D. Mamlouk M, et al. Among authors: bebawy m. J Asthma. 2013 May;50(4):334-41. doi: 10.3109/02770903.2013.773518. Epub 2013 Mar 18. J Asthma. 2013. PMID: 23406450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters